IRVINE, Calif., Jan. 11, 2016 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, today provided preliminary unaudited fourth quarter 2015 revenue results in conjunction with planned meetings January 11-14 surrounding the annual J.P. Morgan Healthcare Conference in San Francisco. Total revenue for the fourth quarter 2015 is expected to be in the range of $78 to $79 million, compared to $74.1 million in the fourth quarter 2014, up approximately 5% to 7% year-over-year, or approximately 9% to 10% in constant currency.
Amit Meridor, Chief Executive Officer of Syneron, said, "Our anticipated record fourth quarter topline performance was driven by the ongoing launches of UltraShape, PicoWay, and Profound. This contributed to growth in excess of 20% in North American product sales during the fourth quarter as compared to the prior year period. Fourth quarter revenue includes $1.6 million from a settlement with an OEM customer of our CoolTouch subsidiary related to the discontinuation of their contract following a change in ownership."
The financial estimates presented above are preliminary and remain subject to management's final review as well as audit by the Company's independent registered accounting firm. The Company intends to report complete fourth quarter and full year 2015 financial results in February. Details regarding the timing of the release of those results, as well as details of a conference call and publicly available webcast, will be announced in a subsequent press release.
About Syneron Candela:
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, Profound and elos Plus.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
SOURCE Syneron Medical Ltd.